Results 61 to 70 of about 1,579,650 (291)
Whole blood was labeled to determine PD-1 and PD-L1 subsets. (A) Histogram plots representatives of one healthy individual and one VL-HIV-1+ individual. PD-L1+ and PD-L1hi were determined in CD4+, in CD8+ and CD19+ cells.
Marjorie Pion (153357) +7 more
core +1 more source
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
Objective Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 ...
Markus Tiemann +3 more
doaj +1 more source
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.
Hyun Tae Lee +8 more
doaj +1 more source
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics.
Yilun Wu +3 more
doaj +1 more source
Background PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC).
Anudari Letian +5 more
doaj +1 more source
(A) Correlation between frequencies of PD-L1 in CD19+ cells and PD-1 in CD4+ T cells and (B) Correlation between frequencies of PD-L1 in CD19+ cells and PD-1 in CD8+ T cells were determined in healthy individuals and in VL-HIV-1+ individuals ...
Marjorie Pion (153357) +7 more
core +1 more source
PD-L1 expression U87MG and LN229.wsp
PD-L1 expression of U87MG and LN229 cells.
Moritz Klawitter (13177230)
core +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source

